Safety assessment of medical cannabis end‑products
Introduction
The safety assessment of medical cannabis end‑products plays a central role in understanding how these therapies perform in real clinical use. As patient numbers grow, regulators need clear insight into how cannabis‑based medicines behave across different treatment settings. Therefore, recent evaluations focus on real‑world data, including adverse reactions, prescription trends, and product quality. These assessments help clinicians and patients make informed decisions. Moreover, they show how regulatory frameworks support safe access to cannabis‑based treatments.
In the latest review period of the year 2025, the Danish Medicines Agency reported no new safety signals, and this outcome strengthens confidence in the current monitoring system. Although the number of users increased significantly to 2,465 patients with 22,410 prescriptions in total, the pattern of reported reactions remained stable. Consequently, the findings suggest that manufacturing standards and prescribing practices work effectively. Still, long‑term data remain limited, especially for THC‑dominant products, and this gap highlights the need for continued vigilance. Additionally, rare but clinically relevant reactions, such as psychiatric symptoms or CBD‑related liver effects, require ongoing observation. Even so, the overall picture indicates that medical cannabis, when used within regulated programmes, maintains a predictable and manageable safety profile. As research advances, future assessments will likely refine our understanding further and support more precise clinical guidance.
Scientific context
Medical cannabis includes products with varying ratios of THC and CBD, and each compound has distinct pharmacological effects. Because of this, safety assessments must consider both short‑term reactions and potential long‑term risks. Furthermore, real‑world data often reveal patterns that controlled trials cannot capture. Thus, annual safety reports remain essential for tracking emerging trends and ensuring that treatment guidelines evolve responsibly.
References
[1] Danish Medicines Agency, link to the report 2025 (Danish language).
Expert’s opinion
The Danish Medicines Agency’s latest review shows that medical cannabis end‑products maintain a stable and predictable safety profile. Despite rising patient numbers, no new safety signals emerged, and reported reactions matched known cannabinoid effects. This consistency indicates effective regulation, though continued monitoring remains essential as long‑term data, especially for THC‑dominant products, are still limited.
